- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Celcuity LLC (CELC)
Track the Celcuity share price today and view real-time CELC share price data, including charts, technicals, and key financials. View the CELC premarket stock price ahead of the market session or assess the after hours quote. Explore CELC stock price movements, trading volume, and market activity across the NASDAQ exchange.
What Is the Celcuity Stock Price Today?
The Celcuity stock price today is 92.00.
What Is the Stock Symbol for Celcuity?
The stock symbol for Celcuity is ""CELC.""
What Stock Exchange Does Celcuity Trade On?
Celcuity is listed and trades on the NASDAQ stock exchange.
Is Celcuity a Good Stock to Buy?
Determining whether Celcuity or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CELC quote. (ISIN: US15102K1007)
What Is the Celcuity Stock Price Today?
The Celcuity stock price today is 92.00.
What Is the Stock Symbol for Celcuity?
The stock symbol for Celcuity is ""CELC.""
What Stock Exchange Does Celcuity Trade On?
Celcuity is listed and trades on the NASDAQ stock exchange.
Is Celcuity a Good Stock to Buy?
Determining whether Celcuity or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CELC quote. (ISIN: US15102K1007)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
83.04
95.56
52 wk Range
44.42
151.02
CELC is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
83.0495.56
52 wk Range
44.42151.02
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CELC Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
160.64
Upside
+74.60%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts do not anticipate the company will be profitable this year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Analyst Ratings
12 Buy
0 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 160.64
(+74.60% Upside)
Celcuity LLC Earnings Call Summary for Q2/2026
- Q2 loss widened to $78.9M or $1.44/share vs. $45.3M year-ago, missing estimates of $1.16/share by 24% amid pre-launch spending surge.
- FDA-approved breast cancer drug REVTORPYK to begin shipping late Q3 2026; NCCN added regimens as preferred Category 1 second-line treatment options.
- Phase III data showed gedatolisib regimens doubled progression-free survival vs. alpelisib (11.1 vs. 5.6 months) in PIK3CA-mutant patients.
- Cash position of $754M expected to fund operations into 2029; SG&A expenses jumped 360% to $35M as company builds commercial infrastructure.
- Supplemental NDA for PIK3CA-mutant expansion planned Q3 2026; prostate cancer data expected Q4 with gross-to-net estimated at 80%.
Last Updated: 14/08/2026, 07:40 am
Read Full TranscriptEarnings
Latest Release
13/08/2026
EPS / Forecast
-1.44 / -1.16
Revenue / Forecast
-- / 4.42M
Compare CELC to Peers and Sector
Metrics to compare | CELC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCELCPeersSector | |
|---|---|---|---|---|
P/E Ratio | −19.9x | −1.5x | −0.4x | |
PEG Ratio | 0.79 | −0.02 | 0.00 | |
Price/Book | −352.2x | 2.0x | 2.6x | |
Price / LTM Sales | - | 7.4x | 3.1x | |
Upside (Analyst Target) | 77.2% | 171.5% | 48.3% | |
Fair Value Upside | Unlock | 20.8% | 6.2% | Unlock |
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company’s lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Celcuity (CELC) Stock Price Today?
The Celcuity stock price today is 92.00 USD.
What Stock Exchange Does Celcuity Trade On?
Celcuity is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Celcuity?
The stock symbol for Celcuity is "CELC."
What Is the Celcuity Market Cap?
As of today, Celcuity market cap is 4.50B USD.
What Is Celcuity's Earnings Per Share (TTM)?
The Celcuity EPS (TTM) is -4.32.
When Is the Next Celcuity Earnings Date?
Celcuity will release its next earnings report on 18/11/2026.
From a Technical Analysis Perspective, Is CELC a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Celcuity Stock Split?
Celcuity has split 0 times.
How Many Employees Does Celcuity Have?
Celcuity has 155 employees.
What is the current trading status of Celcuity (CELC)?
As of 16/08/2026, Celcuity (CELC) is trading at a price of 92.00 USD, with a previous close of 86.60 USD. The stock has fluctuated within a day range of 83.04 USD to 95.56 USD, while its 52-week range spans from 44.42 USD to 151.02 USD.
What Is Celcuity (CELC) Price Target According to Analysts?
The average 12-month price target for Celcuity is 160.64 USD, with a high estimate of 178 USD and a low estimate of 140 USD. 12 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +74.60% Upside potential.
What Is the CELC Premarket Price?
CELC's last pre-market stock price is 86.02 USD. The pre-market share volume is 3,980.00, and the stock has decreased by -0.58, or -0.67%.
What Is the CELC After Hours Price?
CELC's last after hours stock price is 91.99 USD, the stock has decreased by -0.01, or -0.01%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.